Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Genitourinary 1

Conditions

Urologic Neoplasms 1Skin Neoplasms 1Neoplasms 1Melanoma 1Carcinoma, Renal Cell 1

Interventions

Nivolumab 5pembrolizumab 4Ipilimumab 2Drug Therapy 2Biopsy 2poly ICLC 1pertuzumab 1osimertinib 1montanide ISA 51 1liposomal doxorubicin 1flt3 ligand protein 1cobimetinib 1cemiplimab 1cc-486 1brodalumab 1Trastuzumab 1Tissue Banks 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Patient Reported Outcome Measures 1Paclitaxel 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × MART-1 Antigen × Genitourinary × Clear all
NCT00019396 2024-03-04

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

National Cancer Institute (NCI)

Phase 2 Completed
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Neoplasms, Skin Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡